PRLDPrelude Therapeutics Incorporated
$3.63+130% 1Y
$3.63
$1.1952 weeks$6.62
Is the price fair?
What PRLD's price assumes
Prelude Therapeutics Incorporated did not earn a profit over the last twelve months, so it has no trailing P/E and the price is measured against sales instead: 23.4× revenue.
23.4
Price / sales · no P/E: the last twelve months did not end in a profit
- Price / book
- 3.92
Price / book · as of 2026-Q2
Details›
- Price / bookas of 2026-Q2
- 3.92
- EV / EBIToperating margin −301%: the multiple describes the denominator
- not meaningful
- Market capitalisation79.8 million shares, counted Aug 6, 2026
- $290M
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.